A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists.

Trial Profile

A Randomized Double-blind Multiple-dose Placebo-controlled Trial to Establish the Efficacy of QBX258 (Combination of VAK694 and QAX576) in Asthma That is Inadequately Controlled With Inhaled Corticosteroids and Long Acting Beta Agonists.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Dectrekumab/VAK-694 (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 08 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 30 Apr 2014 Planned End Date changed from 1 Nov 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 28 Oct 2013 Planned end date changed from 1 Jun 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top